Jaguar Health Inc (NASDAQ: JAGX) is a pharmaceutical company that commercializes prescription drug products targeting gastrointestinal conditions. Revenue comes from product sales, with Mytesi (crofelemer) approved for HIV-related diarrhea and Gelclair launched in 2024, supplemented by royalty interests sold to lenders that require minimum royalty payments of approximately $27.0 million beginning in 2026. The company operates through its subsidiary Napo Pharmaceuticals, Inc. and has pipeline assets including crofelemer delayed-release tablets targeting chemotherapy-induced diarrhea and IBS-D, crofelemer powder for oral solution targeting short bowel syndrome, and NP-300 tablets for infectious diarrhea. As of the 10-K filed April 7, 2026, the company carried secured debt obligations to Streeterville Capital, LLC, collateralized by NP-300 intellectual property held at Napo, reflecting a debt-heavy capital structure. Sales and marketing headcount expanded in FY2025 to support the Gelclair product launch, with personnel and related benefits rising from $3.4 million in FY2024 to $5.0 million in FY2025.

Revenue model

Transactional prescription drug product sales, primarily Mytesi and Gelclair, with royalty interests sold to lenders generating minimum royalty payment obligations beginning July 2026.

Products and services

Mytesi (crofelemer) for HIV-related diarrhea; Gelclair (launched 2024); crofelemer delayed-release tablets (pipeline, chemotherapy-induced diarrhea and IBS-D); crofelemer powder for oral solution (pipeline, short bowel syndrome and MVID); NP-300 tablets (pipeline, infectious diarrhea).

Customers and end markets

Patients with HIV-related diarrhea, cancer patients receiving outpatient chemotherapy, patients with short bowel syndrome, IBS-D patients, and patients with infectious diarrhea. Distribution through distributors in the US market.

Value-chain role

Pharmaceutical commercialization and drug development company; manufactures through third-party supply agreements (including Alivus Life Sciences Limited for Napo Pharmaceuticals); holds IP and licenses; sells direct via specialty sales force.

Geographic exposure

Primary market is the United States; international funding activities noted in FY2025 officer travel expenses.

Competitors

Three named competitors in IBS-D market (unnamed in filing), One named competitor in short bowel syndrome/MVID market (unnamed in filing)

Source: SEC 10-K, filed 2026-04-07

Industry: Pharmaceutical Preparations Peers: Aytu Biopharma Inc cbdMD Inc PLx Pharma Winddown Corp. Hoth Therapeutics Inc Johnson & Johnson Vyne Therapeutics Inc Pulmatrix Inc Unrivaled Brands, Inc. Weed Inc Virpax Pharmaceuticals, Inc.